視神経症(Optic Neuropathy):治療薬開発パイプライン動向(世界、2015年上半期版)

【英語タイトル】Optic Neuropathy - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6196IDB)・商品コード:GMDHC6196IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月30日
・ページ数:48
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における視神経症(Optic Neuropathy)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・視神経症(Optic Neuropathy)の概要
・視神経症(Optic Neuropathy)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・視神経症(Optic Neuropathy)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・視神経症(Optic Neuropathy)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・視神経症(Optic Neuropathy)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Optic Neuropathy – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Optic Neuropathy – Pipeline Review, H1 2015’, provides an overview of the Optic Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Optic Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Optic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Optic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Optic Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Optic Neuropathy – Overview 7
Pipeline Products for Optic Neuropathy – Comparative Analysis 8
Optic Neuropathy – Therapeutics under Development by Companies 9
Optic Neuropathy – Therapeutics under Investigation by Universities/Institutes 11
Optic Neuropathy – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Optic Neuropathy – Products under Development by Companies 14
Optic Neuropathy – Products under Investigation by Universities/Institutes 15
Optic Neuropathy – Companies Involved in Therapeutics Development 16
Inotek Pharmaceuticals Corporation 16
Neurotech Pharmaceuticals, Inc. 17
PharmatrophiX, Inc. 18
Quark Pharmaceuticals, Inc. 19
Optic Neuropathy – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BA-240 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NT-501 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
QPI-1007 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RPh-201 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for CNS Disorders and Ophthalmology – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Synthetic Peptide to Inhibit Connexin for Optic Neuropathy – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
trabodenoson – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Optic Neuropathy – Recent Pipeline Updates 43
Optic Neuropathy – Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

[List of Tables]
Number of Products under Development for Optic Neuropathy, H1 2015 7
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 16
Optic Neuropathy - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 17
Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H1 2015 18
Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Optic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 43
Optic Neuropathy - Dormant Projects, H1 2015 46

[List of Figures]
Number of Products under Development for Optic Neuropathy, H1 2015 7
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

【掲載企業】

Inotek Pharmaceuticals Corporation
Neurotech Pharmaceuticals, Inc.
PharmatrophiX, Inc.
Quark Pharmaceuticals, Inc.

★調査レポート[視神経症(Optic Neuropathy):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6196IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[視神経症(Optic Neuropathy):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆